Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Universal Off-the-shelf CAR-NK Cells Targeted CD123 (JD123 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia

NCT06201247 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06201247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06201247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Universal Off-the-shelf CAR-NK Cells Targeted CD123 (JD123 Injection) in the Treatment of Refractory or Relapsed CD123-positive Acute Myeloid Leukemia
Lead sponsor
Peking University People's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 30, 2023
Completion date
December 30, 2025
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia refractory, acute myeloid leukemia, in relapse